Over the past few years, China has paid greater attention to the topic of rare diseases. The Chinese Government has made considerable efforts to gradually improve the situation of patients with rare diseases in terms of diagnosis and treatment, access to medication, and affordability of care. The National Health Commission implemented a raft of measures, including the first Catalog of Rare Diseases, establishment of a rare diseases alliance, establishment of the Network for Collaboration in Rare Disease Diagnosis and Treatment, formulation of the Guidelines for the Diagnosis and Treatment of Rare Diseases, sharing of diagnostic and treatment information, and creation of expert committees, to ensure the standardization of rare disease diagnosis and treatment and to promote the improvement of rare disease diagnosis and treatment capabilities nationwide. In order to encourage the research, development, and production of drugs to treat rare diseases, the National Medical Products Administration has drafted a series of policies to accelerate the review and approval of drug registration and to support the research and development of drugs to treat rare diseases. The Ministry of Finance has also helped to implement tax incentives for drugs to treat rare diseases, to encourage the marketing and importation of drugs to treat rare diseases, and to reduce the cost of drugs for patients with rare diseases. Through adjustment of the List of Drugs Covered by National Medical Insurance, the National Healthcare Security Administration has covered an increasing number of drugs to treat rare diseases under basic medical insurance. It has also negotiated to reduce the price of some drugs to treat rare diseases, further reducing the economic burden on patients with rare diseases.
27 October 2020 in IEEE Journal of Biomedical and Health Informatics
Comorbidity is an important factor to consider when trying to predict the cost of treating asthma patients. When an asthmatic patient suffered from comorbidity, the cost of treating such a patient becomes dependent on the nature of the comorbidity. Therefore, lack of recognition of comorbidity on asthmatic patient poses a challenge in predicting the cost of treatment. In this study, we proposed a comorbidity portfolio design that improves the prediction cost of treating asthmatic patients by regrouping frequently occurred comorbidities in different cost groups. In the experiment, predictive models, including logistic regression, random forest, support vector machine, classification regression tree, and backpropagation neural network were trained with real-world data of asthmatic patients from 2012 to 2014 in a large city of China. The 10-fold cross validation and random search algorithm were employed to optimize the hyper-parameters. We recorded significant improvements using our model, which are attributed to comorbidity portfolios in area under curve (AUC) and sensitivity increase of 46.89% (standard deviation: 4.45%) and 101.07% (standard deviation: 44.94%), respectively. In risk analysis of comorbidity on cost, respiratory diseases with a cumulative proportion in the adjusted odds ratio of 36.38% (95%CI: 27.61%, 47.86%) and circulatory diseases with a cumulative proportion in the adjusted odds ratio of 23.83% (95%CI: 15.95%, 35.22%) are the dominant risks of asthmatic patients that affects the treatment cost. It is found that the comorbidity portfolio is robust, and provides a better prediction of the high-cost of treating asthmatic patients. The preliminary characterization of the joint risk of multiple comorbidities posed on cost are also reported. This study will be of great help in improving cost prediction and comorbidity management.
Exposure to adverse life events is linked to somatic disorders. The study aims to evaluate the association between adverse events at varying life stages and the risk of chronic kidney disease (CKD), a condition affecting about 10% population worldwide. This prospective cohort study included 140,997 participants from the UK Biobank. Using survey items related to childhood maltreatment, adulthood adversity and catastrophic trauma, we performed latent class analysis to summarize five distinct patterns of exposure to adverse life events, namely “low-level exposure”, “childhood exposure”, “adulthood exposure”, “sexual abuse” and “child-to-adulthood exposure”. We used Cox proportional hazard regression to evaluate the association of patterns of exposure to adverse life events with CKD, regression-based mediation analysis to decompose the total effect, and gene-environment-wide interaction study (GEWIS) to identify interactions between genetic loci and adverse life events. During a median follow-up of 5.98 years, 2734 cases of incident CKD were identified. Compared with the “low-level exposure” pattern, “child-to-adulthood exposure” was associated with increased risk of CKD (hazard ratio 1.37, 95% CI 1.14 to 1.65). BMI, smoking and hypertension mediated 11.45%, 9.79%, and 4.50% of this total effect, respectively. Other patterns did not show significant results. GEWIS and subsequent analyses indicated that the magnitude of the association between adverse life events and CKD differed according to genetic polymorphisms, and identified potential underlying pathways (e.g., interleukin 1 receptor activity). These findings underscore the importance of incorporating an individual’s psychological encounters and genetic profiles into the precision prevention of CKD.
3 June 2025 in Journal of the American Heart Association
Background: Individuals with chronic kidney disease are at markedly increased risk of incident cardiovascular diseases (CVDs) and premature death. The impact of social isolation on adverse outcomes in chronic kidney disease remained understudied. Methods: This prospective cohort study included 13 090 individuals with chronic kidney disease from the UK Biobank. The exposure was social isolation categorized into 3 levels: least, moderately, and most isolated. Using accelerated failure time and restricted mean survival time analyses. Results: Compared with being least isolated, moderate and most isolation are associated with the acceleration of all‐cause death with a time ratio of 0.87 (95% CI, 0.82–0.93; P <0.001) and 0.76 (95% CI, 0.70–0.82; P <0.001), respectively, and restricted mean survival time differences of 49.1 and 71.6 days within 10 years. We observed marginal association of moderate (time ratio, 0.93 [95% CI, 0.87–0.99]; P =0.039) and most isolation (time ratio, 0.87 [95% CI, 0.79–0.96]; P =0.005) with CVD. But the association was significant only for stroke, not for coronary artery disease. Based on pathways revealed by a directed acyclic graph constructed using the Bayesian network, we conducted inverse odds ratio–weighted mediation to decompose the total effect of social isolation on death, and found that CVD and sarcopenia mediated 21.8% (95% CI, 7.1–43.0) of the total effect of social isolation on death. Conclusions: Social isolation is associated with shortened survival and accelerates the onset of CVD in individuals with chronic kidney disease. Social support warrants attention in the prevention of death and CVD in these high‐risk individuals.
Background: This study aimed to identify novel associations between irritable bowel syndrome (IBS) and a broad range of outcomes. Methods: In total, 346,352 white participants in the U.K. Biobank were randomly divided into two halves, in which a genome-wide association study (GWAS) of IBS and a polygenic risk score (PRS) analysis of IBS using GWAS summary statistics were conducted, respectively. A phenome-wide association study (PheWAS) based on the PRS of IBS was performed to identify disease outcomes associated with IBS. Then, the causalities of these associations were tested by both one-sample (individual-level data in U.K. Biobank) and two-sample (publicly available summary statistics) Mendelian randomization (MR). Sex-stratified PheWAS-MR analyses were performed in male and female, separately. Results: Our PheWAS identified five diseases associated with genetically predicted IBS. Conventional MR confirmed these causal associations between IBS and depression (OR: 1.07, 95%CI: 1.01–1.14, p = 0.02), diverticular diseases of the intestine (OR: 1.13, 95%CI: 1.08–1.19, p = 3.00 × 10−6), gastro-esophageal reflux disease (OR: 1.09, 95%CI: 1.05–1.13, p = 3.72 × 10−5), dyspepsia (OR: 1.21, 95%CI: 1.13–1.30, p = 9.28 × 10−8), and diaphragmatic hernia (OR: 1.10, 95%CI: 1.05–1.15, p = 2.75 × 10−5). The causality of these associations was observed in female only, but not men. Conclusions: Increased risks of IBS is found to cause a series of disease outcomes. Our findings support further investigation on the clinical relevance of increased IBS risks with mental and digestive disorders.
13 June 2022 in IEEE Journal of Biomedical and Health Informatics
The evolving disease spectrum poses significant challenges to the asthma management, thus worsening health quality and increased financial burden on patients. However, potential dependency pattern in comorbidity spectrum remains unclear. We built comorbidity networks based on Bayesian networks utilizing 19604 asthma-patient hospitalization data to investigate dependency patterns among asthma comorbidities. We analyze static properties and trajectory behaviors of gender- and age-stratified asthmatic comorbidity networks. Results suggest that chronic obstructive pulmonary disease, respiratory failure, hypertension, atherosclerosis, and gastritis and duodenitis are the hubs of the asthma comorbidity network. They have a strong dependency pattern, while most of the associations among other comorbidities are sparse and weak. The strength of association between comorbidities is higher in female asthmatics than in males. Although the comorbidity network in children with asthma is simple and stable, the onset of common comorbidities as they age will enhance the association between comorbidities and thus increase the risk of developing other comorbidities. Furthermore, the more attributes of comorbidities, the stronger association with each other, and the greater risk of causing high treatment costs. Our study will help to dissect the asthma co-morbidity network and provide a basis for improving asthma management and cost control.